CNMD Stock Analysis: Buy, Sell, or Hold?
CNMD - CONMED Corporation
$35.95
1.39 (4.02%)
▲
5d:
+10.34%
30d:
+1.32%
90d:
-1.88%
BUY
HIGH Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Jul 29, 2026
30d
Get Alerted When CNMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CNMD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CNMD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$53.97
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$33.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CNMD is currently trading at $35.95, which is considered slightly high relative to its 30-day fair value range of $33.55 to $36.33. The stock's valuation (Forward PE: 7.5) is in line with its historical norms (8.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.7% over the next few years. This pessimistic expectation contrasts with the company's recent 136.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CNMD is in a strong downtrend. The price is approaching resistance at $36.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: CNMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.60 (+10.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CNMD is in a strong downtrend. The price is approaching resistance at $36.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: CNMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.60 (+10.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$33.55 -
$36.33
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading below Wall St target ($39.60)
Trading Range Analysis
30-Day Trading Range
$33.55 -
$36.33
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$31.44
Resistance Level
$36.04
Current Trend
Strong Downtrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.51
Wall Street Target
$39.60
(+10.2%)
Revenue Growth (YoY)
-1.3%
Earnings Growth (YoY)
136.8%
Profit Margin
4.0%
Valuation Discount vs History
-2.7% cheaper
PE vs Historical
7.5 vs 8.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.7%
(market-implied from PE analysis)
1-Year Target
$34.98
(-3%)
2-Year Target
$34.03
(-5%)
3-Year Target
$33.12
(-8%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
$35.73
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.7%)
$137.62
(+283%)
Base:
(SPY PE: 7.5, Growth: 9.7%)
$47.44
(+32%)
Bear:
(PE: 6.4, Growth: 9.7%)
$40.33
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 19.53 | Current EPS (TTM): $1.77
Bull Case
$76.03
(+112%)
Analyst growth 100.0%, PE expands to 21.5
Base Case
$69.12
(+92%)
Market implied 100.0%, PE stable at 19.5
Bear Case
$23.50
(-35%)
Severe decline -20.0%, PE contracts to 16.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.5 to 8.1
Stabilization Target:
$38.78
(+7.9%)
PE Expansion Potential:
+7.9%
Share & Embed Analysis
Last updated: June 28, 2026 7:52 AM ET
Data refreshes hourly during market hours. Next update: 8:52 AM
Data refreshes hourly during market hours. Next update: 8:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 66 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 55 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 68 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 65 BUY |
